Geron Discontinues Phase 3 Trial Evaluating Imetelstat in Myelofibrosis

10:11 AM EDT, 10/28/2026 (MT Newswires) -- Geron (GERN) is discontinuing its phase 3 trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis, based on a recommendation from the independent Data Monitoring Committee, the company said Wednesday. The committee said that the trial was unlikely to meet its primary endpoint of overall survival, according to a statement. Geron said it will conduct a detailed analysis of the trial data and share its findings with the scientific community. The company's shares dropped more than 20% in morning trading. Price: 0.91, Change: -0.24, Percent Change: -20.52